Arsenal Biosciences, a clinical-stage programmable cell therapy company focused on engineering advanced CAR T cell therapies for solid tumors, today announced that Bristol Myers Squibb has exercised its exclusive license option for ArsenalBio’s AB-4000 series, the lead collaboration program generated under the multi-program agreement signed in December 2020. This milestone further strengthens the collaboration to advance next-generation T-cell therapies for the treatment of solid tumors.
“This milestone underscores the confidence Bristol Myers Squibb has in ArsenalBio’s programmable T cell platform and our shared vision to develop transformative cell therapies for solid tumors,” said Ken Drazan, M.D., ArsenalBio’s Chairman and CEO. “Our collaboration provides increasing opportunities to address the multifactorial challenge of treating solid tumors through programmable cell engineering. We look forward to continuing our work with Bristol Myers Squibb and progressing the AB-4000 series toward clinical development to potentially benefit patients with solid tumors.”
Alex Marson and Kole Roybal are the lead UCSF inventors.